Circulating tumor cells mirror bone metastatic phenotype in prostate cancer

Andreas Josefsson; Karin Larsson; Marianne Månsson; Jens Björkman; Eva Rohlova; Daniel Åhs; Helena Brisby; Jan-Erik Damber; Karin Welén

doi:10.18632/oncotarget.25634

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Circulating tumor cells mirror bone metastatic phenotype in prostate cancer

Andreas Josefsson, Karin Larsson, Marianne Månsson, Jens Björkman, Eva Rohlova, Daniel Åhs, Helena Brisby, Jan-Erik Damber and Karin Welén _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:29403-29413. https://doi.org/10.18632/oncotarget.25634

Metrics: PDF 1727 views | HTML 2763 views | ?

Abstract

Andreas Josefsson1, Karin Larsson1, Marianne Månsson1, Jens Björkman3, Eva Rohlova3,4,5,6, Daniel Åhs1, Helena Brisby2, Jan-Erik Damber1 and Karin Welén1

1Sahlgrenska Cancer Center, Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

2Department of Orthopaedics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

3TATAA Biocenter AB, Gothenburg, Sweden

4Department of Anthropology and Human Genetics, Faculty of Science, Charles University, Prague, Czech Republic

5Laboratory of Gene Expression, Institute of Biotechnology CAS, BIOCEV, Vestec, Czech Republic

6Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

Correspondence to:

Karin Welén, email: [email protected]

Keywords: liquid biopsies; circulating tumor cells; skeletal metastases of prostate cancer

Received: April 19, 2018 Accepted: May 17, 2018 Published: June 29, 2018

ABSTRACT

Circulating tumor cells (CTCs) are promising biomarkers in prostate cancer (PC) because they derive from primary tumor and metastatic tissues. In this study, we used quantitative real-time PCR (qPCR) to compare the expression profiles of 41 PC-related genes between paired CTC and spinal column metastasis samples from 22 PC patients that underwent surgery for spinal cord compression. We observed good concordance between the gene expression profiles in the CTC and metastasis samples in most of the PC patients. Expression of nine genes (AGR2, AKR1C3, AR, CDH1, FOLH1, HER2, KRT19, MDK, and SPINK1) showed a significant correlation between the CTC and metastasis samples. Hierarchical clustering analysis showed a similar grouping of PC patients based on the expression of these nine genes in both CTC and metastasis samples. Our findings demonstrate that CTCs mirror gene expression patterns in tissue metastasis samples from PC patients. Although low detection frequency of certain genes is a limitation in CTCs, our results indicate the potential for CTC phenotyping as a tool to improve individualized therapy in metastatic prostate cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25634

Publication Alerts

Research Papers:

Circulating tumor cells mirror bone metastatic phenotype in prostate cancer

Abstract